Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) was down 1.8% during mid-day trading on Monday . The company traded as low as $35.38 and last traded at $35.48. 181,388 shares traded hands during trading, an increase of 262% from the average session volume of 50,104 shares. The stock had previously closed at $36.12.
Neoleukin Therapeutics Trading Down 1.8%
The company’s 50 day simple moving average is $36.83 and its 200 day simple moving average is $29.76. The stock has a market capitalization of $333.44 million, a PE ratio of -11.41 and a beta of 1.11.
Neoleukin Therapeutics Company Profile
Neoleukin Therapeutics, Inc was a clinical-stage biotechnology company focused on developing computationally designed protein therapeutics for cancer and other serious diseases. The company was headquartered in Seattle, Washington, and operated primarily in the United States.
Its lead program was NL-201, an engineered cytokine designed to mimic the activities of interleukin-2 and interleukin-15. Neoleukin investigated NL-201 as an immunotherapy intended to stimulate immune cells that can recognize and attack tumors, including in patients with advanced solid cancers.
Read More
- Five stocks we like better than Neoleukin Therapeutics
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
